UNSPSC 51152017: Baclofen

This classification denotes a muscle relaxant with the molecular formula C10H12ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H789N3FKE8, chemically known as hydrocinnamic acid, beta-(aminomethyl)-p-chloro- but generally known as baclofen, which bears US NIH Compound Identifier 2284. European Medicines Agency schedules Baclofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05667MIG.

UNSPSC 51152017 Baclofen is a Commodity code that in recent state and local procurement activity has been applied to pharmaceutical procurements, though the recent opportunities posted under this code diverge from baclofen specifically. The Seminole County, Florida IFB (IFB60459723LAS, posted June 30, 2026, due July 26, 2026) solicits naloxone and drug deactivation systems rather than baclofen; the Texas Health and Human Services Commission RFI (HHS0017013, posted April 3, 2026) seeks vendor capabilities for a therapeutic pharmacy initiative direct-to-manufacturer prescriptions program without naming a specific pharmaceutical product. The code shows minimal activity aligned to its nominal scope — state and local procurement databases tag pharmaceutical and pharmacy-benefit opportunities under this code irregularly, and recent opportunities reflect broader pharmacy and pharmaceutical distribution needs rather than baclofen procurement specifically.

The issuing bodies are mixed across state health agencies and county health departments. Seminole County's procurement involves quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with an initial two-year contract term and one-year renewal option. The Texas HHS Commission RFI is exploratory, designed to gather vendor capability information before issuing a formal RFP for direct-to-manufacturer prescription programs. Geographic activity appears concentrated in Florida and Texas, though the Texas RFI scope extends statewide. The mismatch between the code's nominal scope (baclofen, a muscle relaxant) and the recent solicitations (naloxone and pharmacy benefit distribution) suggests either miscoding by the issuing bodies or that the code has been repurposed for broader pharmaceutical procurement in state and local systems. Firms pursuing pharmaceutical distribution or pharmacy benefit management contracts should verify code alignment in posting notices rather than relying on this code as a reliable indicator of baclofen-specific demand.